Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

A single fast radio burst localized to a massive galaxy at cosmological distance.

Bannister KW, Deller AT, Phillips C, Macquart JP, Prochaska JX, Tejos N, Ryder SD, Sadler EM, Shannon RM, Simha S, Day CK, McQuinn M, North-Hickey FO, Bhandari S, Arcus WR, Bennert VN, Burchett J, Bouwhuis M, Dodson R, Ekers RD, Farah W, Flynn C, James CW, Kerr M, Lenc E, Mahony EK, O'Meara J, Osłowski S, Qiu H, Treu T, U V, Bateman TJ, Bock DC, Bolton RJ, Brown A, Bunton JD, Chippendale AP, Cooray FR, Cornwell T, Gupta N, Hayman DB, Kesteven M, Koribalski BS, MacLeod A, McClure-Griffiths NM, Neuhold S, Norris RP, Pilawa MA, Qiao RY, Reynolds J, Roxby DN, Shimwell TW, Voronkov MA, Wilson CD.

Science. 2019 Aug 9;365(6453):565-570. doi: 10.1126/science.aaw5903. Epub 2019 Jun 27.

PMID:
31249136
2.

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.

Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, Cramp ME, Cooper C, Foxton M, Rodriguez CF, Esteban R, Hyland R, Lu S, Kirby BJ, Meng A, Markova S, Dvory-Sobol H, Osinusi AO, Bruck R, Ampuero J, Ryder SD, Agarwal K, Fox R, Shaw D, Haider S, Willems B, Lurie Y, Calleja JL, Gane EJ.

J Hepatol. 2019 Jun 11. pii: S0168-8278(19)30343-5. doi: 10.1016/j.jhep.2019.05.028. [Epub ahead of print]

3.

The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England.

Harrison GI, Murray K, Gore R, Lee P, Sreedharan A, Richardson P, Hughes AJ, Wiselka M, Gelson W, Unitt E, Ratcliff K, Orton A, Trinder K, Simpson C, Ryder SD, Oelbaum S, Foster GR, Christian A, Smith S, Thomson BJ, Reynolds R, Harris M, Hickman M, Irving WL.

Addiction. 2019 Jun;114(6):1113-1122. doi: 10.1111/add.14569. Epub 2019 Mar 12.

PMID:
30694582
4.

Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients.

Bradley C, Scott RA, Cox E, Palaniyappan N, Thomson BJ, Ryder SD, Irving WL, Aithal GP, Guha IN, Francis S.

Eur Radiol. 2019 Jun;29(6):3100-3107. doi: 10.1007/s00330-018-5788-1. Epub 2018 Nov 30.

5.

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.

Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, Kwo PY, Weiland O, Villa E, Heo J, Gane E, Ryder SD, Welzel TM, Ruane PJ, Agarwal K, Ng TI, Xue Z, Lovell SS, Krishnan P, Kopecky-Bromberg S, Trinh R, Mensa FJ, Wyles DL.

J Viral Hepat. 2019 Mar;26(3):337-349. doi: 10.1111/jvh.13038. Epub 2018 Dec 11.

PMID:
30421537
6.

NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid.

de Graaf KL, Lapeyre G, Guilhot F, Ferlin W, Curbishley SM, Carbone M, Richardson P, Moreea S, McCune CA, Ryder SD, Chapman RW, Floreani A, Jones DE, de Min C, Adams DH, Invernizzi P.

Hepatol Commun. 2018 Mar 23;2(5):492-503. doi: 10.1002/hep4.1170. eCollection 2018 May.

7.

Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.

Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A, Forton DM, Fox R, Gordon F, Rosenberg WM, Mutimer DJ, Du J, Gilbert CL, Asante-Appiah E, Wahl J, Robertson MN, Barr E, Haber B.

Hepatology. 2018 Jun;67(6):2113-2126. doi: 10.1002/hep.29852. Epub 2018 Apr 19.

PMID:
29473975
8.

Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography.

Harman DJ, Ryder SD, James MW, Wilkes EA, Card TR, Aithal GP, Guha IN.

Aliment Pharmacol Ther. 2018 Feb;47(4):504-515. doi: 10.1111/apt.14463. Epub 2017 Dec 6.

9.

Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma.

Fateen W, Khan F, O'Neill RJ, James MW, Ryder SD, Aithal GP.

J Hepatocell Carcinoma. 2017 Oct 16;4:123-130. doi: 10.2147/JHC.S144068. eCollection 2017.

10.

The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS).

Hudson M, Radwan A, Di Maggio P, Cipelli R, Ryder SD, Dillon JF, Cash WJ, Przemioslo RT, Wright M, Shawcross DL, Jalan R, Saksena S, Allison M, Richardson P, Farrington E, Aspinall RJ.

Frontline Gastroenterol. 2017 Oct;8(4):243-251. doi: 10.1136/flgastro-2016-100792. Epub 2017 Apr 7.

11.

Screening for hepatocellular carcinoma: patient selection and perspectives.

Fateen W, Ryder SD.

J Hepatocell Carcinoma. 2017 May 17;4:71-79. doi: 10.2147/JHC.S105777. eCollection 2017. Review.

12.

In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA.

Vergis N, Atkinson SR, Knapp S, Maurice J, Allison M, Austin A, Forrest EH, Masson S, McCune A, Patch D, Richardson P, Gleeson D, Ryder SD, Wright M, Thursz MR.

Gastroenterology. 2017 Apr;152(5):1068-1077.e4. doi: 10.1053/j.gastro.2016.12.019. Epub 2016 Dec 30.

13.

Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals.

Faria R, Woods B, Griffin S, Palmer S, Sculpher M, Ryder SD.

Aliment Pharmacol Ther. 2016 Oct;44(8):866-76. doi: 10.1111/apt.13775. Epub 2016 Aug 25.

14.

The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches.

Thiagarajan P, Ryder SD.

Curr Opin Infect Dis. 2015 Dec;28(6):572-5. doi: 10.1097/QCO.0000000000000204. Review.

PMID:
26524329
15.

The hepatitis C revolution part 1: antiviral treatment options.

Thiagarajan P, Ryder SD.

Curr Opin Infect Dis. 2015 Dec;28(6):563-71. doi: 10.1097/QCO.0000000000000205. Review.

PMID:
26524328
16.

Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography.

Harman DJ, Ryder SD, James MW, Jelpke M, Ottey DS, Wilkes EA, Card TR, Aithal GP, Guha IN.

BMJ Open. 2015 May 3;5(4):e007516. doi: 10.1136/bmjopen-2014-007516.

17.

Chronic hepatitis C - what do the new drugs offer and who should get them first?

Ryder SD.

Clin Med (Lond). 2015 Apr;15(2):197-200. doi: 10.7861/clinmedicine.15-2-197.

18.

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.

Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, McHutchison JG, Gane EJ, Foster GR.

J Hepatol. 2015 Mar;62(3):533-40. doi: 10.1016/j.jhep.2014.10.035. Epub 2014 Oct 30.

PMID:
25450717
19.

Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.

Cramp ME, Rosenberg WM, Ryder SD, Blach S, Parkes J.

BMC Gastroenterol. 2014 Aug 7;14:137. doi: 10.1186/1471-230X-14-137.

20.

Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts.

McLernon DJ, Donnan PT, Sullivan FM, Roderick P, Rosenberg WM, Ryder SD, Dillon JF.

BMJ Open. 2014 Jun 2;4(6):e004837. doi: 10.1136/bmjopen-2014-004837.

21.

Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.

Miller MH, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, Leen C, Millson C, Ryder SD, Tait J, Ustianowski A, Dillon JF; British Viral Hepatitis group; British Society of Gastroenterology Liver Committee; British Association for the Study of Liver; Scottish Society of Gastroenterology; Scottish Viral Hepatitis group; Scottish Viral Hepatitis Nurses group.

Aliment Pharmacol Ther. 2014 Jun;39(12):1363-75. doi: 10.1111/apt.12764. Epub 2014 Apr 22.

22.

Strategies to manage hepatitis C virus (HCV) disease burden.

Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus AL, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E.

J Viral Hepat. 2014 May;21 Suppl 1:60-89. doi: 10.1111/jvh.12249.

PMID:
24713006
23.

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C.

J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248.

PMID:
24713005
24.

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ.

J Viral Hepat. 2014 May;21 Suppl 1:5-33. doi: 10.1111/jvh.12247. Review.

PMID:
24713004
25.

Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.

Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K.

Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5. doi: 10.1016/j.cgh.2014.01.040. Epub 2014 Feb 12.

PMID:
24530600
26.

The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).

McLernon DJ, Dillon JF, Sullivan FM, Roderick P, Rosenberg WM, Ryder SD, Donnan PT.

PLoS One. 2012;7(12):e50965. doi: 10.1371/journal.pone.0050965. Epub 2012 Dec 14.

27.

The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call.

Tedder RS, Rodger AJ, Fries L, Ijaz S, Thursz M, Rosenberg W, Naoumov N, Banatvala J, Williams R, Dusheiko G, Chokshi S, Wong T, Rosenberg G, Moreea S, Bassendine M, Jacobs M, Mills PR, Mutimer D, Ryder SD, Bathgate A, Hussaini H, Dillon JF, Wright M, Bird G, Collier J, Anderson M, Johnson AM; Collaborative UK Study of Chronic Hepatitis B Infection (CUSHI-B) Study Group.

Clin Infect Dis. 2013 Apr;56(7):951-60. doi: 10.1093/cid/cis1013. Epub 2012 Dec 7.

PMID:
23223601
28.

The performance of transient elastography compared to clinical acumen and routine tests - what is the incremental diagnostic value?

Dolman GE, Nieboer D, Steyerberg EW, Harris S, Ferguson A, Zaitoun AM, Ryder SD, James MW, Aithal GP, Guha IN.

Liver Int. 2013 Feb;33(2):172-9. doi: 10.1111/liv.12017. Epub 2012 Nov 8.

PMID:
23136951
29.

Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute variceal haemorrhage.

Harman DJ, McCorry RB, Jacob RP, Lim TR, O'Neill R, Ryder SD, James MW, Aithal GP, Guha IN.

Eur J Gastroenterol Hepatol. 2013 Feb;25(2):201-7. doi: 10.1097/MEG.0b013e32835a4cb0.

PMID:
23089879
30.

The utility of scoring systems in predicting early and late mortality in alcoholic hepatitis: whose score is it anyway?

Palaniyappan N, Subramanian V, Ramappa V, Ryder SD, Kaye P, Aithal GP.

Int J Hepatol. 2012;2012:624675. doi: 10.1155/2012/624675. Epub 2012 Sep 4.

31.

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.

Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM.

Hepatology. 2013 Jan;57(1):103-11. doi: 10.1002/hep.26030.

PMID:
22930399
32.

Getting involved in clinical trials research in the UK: how can Clinical Research Networks help?

Hull MA, Yiannakou Y, Gower J, Ryder SD, Bloom SL, Rees CR.

Frontline Gastroenterol. 2012 Apr;3(2):66-71. doi: 10.1136/flgastro-2011-100083. Epub 2012 Jan 10. Review.

33.

Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2012 May;24(5):543-50. doi: 10.1097/MEG.0b013e3283513e69.

PMID:
22337287
34.

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.

Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1.

35.

A complex multi-notch astronomical filter to suppress the bright infrared sky.

Bland-Hawthorn J, Ellis SC, Leon-Saval SG, Haynes R, Roth MM, Löhmannsröben HG, Horton AJ, Cuby JG, Birks TA, Lawrence JS, Gillingham P, Ryder SD, Trinh C.

Nat Commun. 2011 Dec 6;2:581. doi: 10.1038/ncomms1584.

PMID:
22146400
36.

Effectiveness of a nurse-led alcohol liaison service in a secondary care medical unit.

Ryder SD, Aithal GP, Holmes M, Burrows M, Wright NR.

Clin Med (Lond). 2010 Oct;10(5):435-40.

37.

Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease.

Rakha EA, Adamson L, Bell E, Neal K, Ryder SD, Kaye PV, Aithal GP.

J Clin Pathol. 2010 Sep;63(9):790-5. doi: 10.1136/jcp.2010.079145.

PMID:
20819880
38.

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice.

Grishchenko M, Grieve RD, Sweeting MJ, De Angelis D, Thomson BJ, Ryder SD, Irving WL; Trent HCV Study Group.

Int J Technol Assess Health Care. 2009 Apr;25(2):171-80. doi: 10.1017/S0266462309090229. Epub 2009 Mar 31.

39.

Autoantibodies in chronic hepatitis C virus infection and their association with disease profile.

Williams MJ, Lawson A, Neal KR, Ryder SD, Irving WL; Trent HCV Group.

J Viral Hepat. 2009 May;16(5):325-31. doi: 10.1111/j.1365-2893.2008.01035.x. Epub 2009 Mar 3.

PMID:
19302340
40.

Fast-food hyper-alimentation and exercise restriction in healthy subjects.

Johnston RD, Aithal GP, Ryder SD, MacDonald IA.

Gut. 2009 Mar;58(3):469-70; author reply 470. No abstract available.

PMID:
19211862
41.

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.

Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J.

Gastroenterology. 2008 Oct;135(4):1176-84. doi: 10.1053/j.gastro.2008.06.047. Epub 2008 Jun 25.

PMID:
18718471
42.

Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management.

Thomson BJ, Kwong G, Ratib S, Sweeting M, Ryder SD, De Angelis D, Grieve R, Irving WL; Trent HCV Study Group.

J Viral Hepat. 2008 Apr;15(4):271-8. Epub 2007 Dec 11.

PMID:
18086181
43.

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.

Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM.

Hepatology. 2008 Feb;47(2):455-60.

PMID:
18038452
44.

Outcome of hepatitis C infection: bleak or benign?

Ryder SD.

J Hepatol. 2007 Jul;47(1):4-6. Epub 2007 Apr 20. No abstract available.

PMID:
17512628
45.

The natural history of hepatitis C with severe hepatic fibrosis.

Lawson A, Hagan S, Rye K, Taguri N, Ratib S, Zaitoun AM, Neal KR, Ryder SD, Irving WL; Trent HCV Study Group.

J Hepatol. 2007 Jul;47(1):37-45. Epub 2007 Mar 7.

PMID:
17400322
46.

Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex.

Brown KS, Keogh MJ, Tagiuri N, Grainge MJ, Presanis JS, Ryder SD, Irving WL, Ball JK, Sim RB, Hickling TP.

Clin Exp Immunol. 2007 Jan;147(1):90-8.

47.

Mannan binding lectin and viral hepatitis.

Brown KS, Ryder SD, Irving WL, Sim RB, Hickling TP.

Immunol Lett. 2007 Jan 15;108(1):34-44. Epub 2006 Nov 20. Review.

PMID:
17157924
48.

Biochemical "liver function tests".

Smellie WS, Ryder SD.

BMJ. 2006 Sep 2;333(7566):481-3. No abstract available.

49.

Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens.

Irving WL, Smith S, Cater R, Pugh S, Neal KR, Coupland CA, Ryder SD, Thomson BJ, Pringle M, Bicknell M, Hippisley-Cox J.

J Viral Hepat. 2006 Apr;13(4):264-71.

PMID:
16611193
50.

Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease.

Lawson A, Ryder SD.

Eur J Gastroenterol Hepatol. 2006 Apr;18(4):343-7. Review.

PMID:
16538105

Supplemental Content

Loading ...
Support Center